Roche: Tecentriq is just as effective subcutaneously

(CercleFinance.com) - Roche announced on Thursday that a Phase III study had established that the subcutaneous formulation of its anticancer drug Tecentriq is just as effective as an intravenous administration.


The pharmaceutical company said that this method of administration under the skin, using a needle, has the advantage of shortening the administration time to about seven minutes, compared with 30 to 60 minutes by intravenous route.

In a statement, Roche said it had submitted the results to health authorities for approval in all indications where the intravenous formulation of Tecentriq is already approved.

If approved, Tecentriq would become Roche's fourth cancer drug to be administered subcutaneously.


Copyright (c) 2022 CercleFinance.com. All rights reserved.